Ascent Group LLC Has $4.91 Million Stake in Pfizer Inc. $PFE

Ascent Group LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 197,114 shares of the biopharmaceutical company’s stock after acquiring an additional 32,990 shares during the quarter. Ascent Group LLC’s holdings in Pfizer were worth $4,908,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 2,087 shares during the period. United Bank lifted its holdings in Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Capital Advisors Wealth Management LLC boosted its stake in Pfizer by 8.2% in the 2nd quarter. Capital Advisors Wealth Management LLC now owns 9,941 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 752 shares during the period. Finally, Cresset Asset Management LLC grew its holdings in Pfizer by 49.6% in the 2nd quarter. Cresset Asset Management LLC now owns 709,582 shares of the biopharmaceutical company’s stock valued at $17,200,000 after buying an additional 235,163 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the company a “positive” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada initiated coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. Guggenheim boosted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. Finally, UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Trading Up 0.2%

Shares of PFE opened at $28.37 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.75. The firm has a market cap of $161.29 billion, a price-to-earnings ratio of 20.86 and a beta of 0.43. The business’s fifty day moving average is $27.09 and its 200-day moving average is $25.83.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the company earned $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.